AMRX - Amneal Pharmaceuticals, Inc.
6.44 0.00 (0.00%)
After hours: 6:10PM EDT
| Previous Close | 6.90 |
| Open | 6.87 |
| Bid | 6.36 x 1100 |
| Ask | 7.03 x 800 |
| Day's Range | 6.38 - 6.96 |
| 52 Week Range | 6.38 - 24.48 |
| Volume | 1,132,155 |
| Avg. Volume | 1,040,979 |
| Market Cap | 1.924B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | Aug 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.82 |
- GlobeNewswire•7 days ago
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Rockwell Medical, Amneal Pharmaceuticals, Kraft Heinz, and Intuit and Encourages Investors to Contact the Firm
NEW YORK, June 18, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against certain officers and directors of Rockwell Medical, Amneal Pharmaceuticals,.
- PR Newswire•10 days ago
AMNEAL INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
NEW ORLEANS , June 14, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
- SmarterAnalyst•13 days ago
Barclays Has New Plays for Healthcare Fans
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Will Qualcomm (QCOM) Stock Win Again? Canaccord Remains Bullish * CannTrust Holdings (CTST): Even With Entry Into U.S. Market, Investors Must Remain Patient * Deutsche Bank Remains Bullish on UBER and Facebook Stocks * Facebook's (FB) Libra Could Be the Next Big Thing
- Business Wire•19 days ago
Amneal Pharmaceuticals to Present at Upcoming Investor Conferences
Amneal Pharmaceuticals, Inc. today announced that members of management will participate at the following upcoming investor conferences:
- Investor's Business Daily•last month
An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars
Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.
- Simply Wall St.•last month
Need To Know: Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Insiders Have Been Selling Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
- Business Wire•last month
AMNEAL INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Amneal Pharmaceuticals, Inc. - AMRX
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (AMRX). For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities and relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products. The Company has been sued in a securities class action lawsuit for failing to disclose material information to shareholders, violating federal securities laws, which is ongoing.
- Business Wire•last month
Amneal Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference
Amneal Pharmaceuticals, Inc. today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m.
- PR Newswire•last month
AMNEAL INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Amneal Pharmaceuticals, Inc. To Contact The Firm
NEW YORK , May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") ...
Motley Fool•2 months agoAmneal Pharmaceuticals, Inc. (AMRX) Q1 2019 Earnings Call Transcript
AMRX earnings call for the period ending March 31, 2019.
- Motley Fool•2 months ago
Why Amneal Pharmaceuticals Stock Is Cratering Today
Investors were none too pleased with Amneal's first-quarter performance. Here's why.
- Zacks•2 months ago
Amneal Pharmaceuticals (AMRX) Misses Q1 Earnings Estimates
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Amneal: 1Q Earnings Snapshot
The Bridgewater, New Jersey-based company said it had a loss of 37 cents per share. Earnings, adjusted for one-time gains and costs, were 14 cents per share. The results missed Wall Street expectations. ...
- Business Wire•2 months ago
Amneal Reports First Quarter 2019 Financial Results
‒ Q1 2019 Net Revenue of $446 Million; GAAP Loss per share of $0.37; Combined Adjusted Diluted EPS of $0.14 ‒
- Insider Monkey•2 months ago
Here’s What Hedge Funds Think About Amneal Pharmaceuticals, Inc. (AMRX)
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- Business Wire•3 months ago
Amneal to Report First Quarter 2019 Results on May 9, 2019
Amneal Pharmaceuticals, Inc. will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on May 9, 2019.
- Business Wire•3 months ago
Amneal Names Pradeep Bhadauria as Chief Scientific Officer
Amneal Pharmaceuticals, Inc. (AMRX), today announced that the company has appointed Pradeep Bhadauria as Chief Scientific Officer (CSO), effective immediately. Pradeep brings significant R&D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies.
- PR Newswire•3 months ago
Amneal Announces Agreement with Zentiva to Divest Creo Pharma
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the company's commercial operations in the United Kingdom. "We believe that the value created by our commercial operations in the UK will be better maximized by Zentiva, which will gain additional products and enhanced competitive market share position as a result of this transaction," said Rob Stewart, President and CEO of Amneal.
- GuruFocus.com•3 months ago
Amneal Pharmaceuticals Inc (AMRX) President and CEO Robert A Stewart Bought $202,640 of Shares
President and CEO of Amneal Pharmaceuticals Inc (NYSE:AMRX) Robert A Stewart bought 17,000 shares of AMRX on 03/12/2019 at an average price of $11.92 a share.
- PR Newswire•3 months ago
Amneal Announces Launch of Rivastigmine Transdermal System
BRIDGEWATER, N.J., March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has launched its generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval of its Rivastigmine Transdermal System in January 2019, and has received final approval on 10 Abbreviated New Drug Applications this year. "We are pleased to have received approval on and launched the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," said Rob Stewart, President and CEO of Amneal.
- PR Newswire•4 months ago
Amneal Pharmaceuticals to Present at the Barclays Global Healthcare Conference
BRIDGEWATER, N.J. , March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare ...
- Zacks•4 months ago
New Strong Sell Stocks for March 5th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today
- GuruFocus.com•4 months ago
Amneal Pharmaceuticals Inc (AMRX) Files 10-K for the Fiscal Year Ended on December 31, 2018
Amneal Pharmaceuticals Inc (NYSE:AMRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
- Zacks•4 months ago
Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher
Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Motley Fool•4 months agoAmneal Pharmaceuticals, Inc. (AMRX) Q4 2018 Earnings Conference Call Transcript
AMRX earnings call for the period ending December 31, 2018.
